Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...
Takeda Pharmaceutical Company Limited (TSE:4502...
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Join the National Investor Network and get the latest information with your interests in mind.